Drug Trial Radar · NCT07155226
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Jan 9, 2026
Primary completion
Feb 15, 2029
Study completion Feb 15, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
Conditions
- Acute Lymphoblastic Leukaemia
- Acute Myeloid Leukaemia
- Higher-risk Myelodysplastic Syndromes
Interventions
AZD3632Drug
AZD3632 will be administered orally.
PosaconazoleDrug
Posaconazole will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Module 1: Number of participants with dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)Time frame: Up to 3 years 1 month
- Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)Time frame: Up to 30 days after last dose (approximately 3 years 1 month)
Locations
30 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Decatur, Illinois · Recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Chapel Hill, North Carolina · Not yet recruiting
Research Site
Durham, North Carolina · Recruiting
Research Site
Portland, Oregon · Suspended
Research Site
Houston, Texas · Recruiting
Research Site
Fitzroy, Australia · Suspended
Research Site
Perth, Australia · Suspended
Research Site
Toronto, Ontario, Canada · Suspended
Research Site
Montreal, Quebec, Canada · Suspended
Research Site
Copenhagen, Denmark · Recruiting
Research Site
Dresden, Germany · Recruiting
Research Site
Frankfurt A. Main, Germany · Recruiting
Research Site
Halle, Germany · Recruiting
Research Site
Heidelberg, Germany · Recruiting
Research Site
München, Germany · Recruiting
Research Site
Ulm, Germany · Recruiting
Research Site
Bologna, Italy · Recruiting
Research Site
Ravenna, Italy · Recruiting
Research Site
Bunkyō City, Japan · Recruiting
Research Site
Kashiwa, Japan · Not yet recruiting
Research Site
Okayama, Japan · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Edinburgh, United Kingdom · Recruiting
Research Site
London, United Kingdom · Not yet recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Manchester, United Kingdom · Recruiting
Research Site
Newcastle, United Kingdom · Suspended
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.